ERCC8 293T Cell Transient Overexpression Lysate(Denatured)
- Known as:
- ERCC8 293T Cell Transient Overexpression Lysate(Denatured)
- Catalog number:
- H00001161-T01
- Product Quantity:
- 100 uL
- Category:
- -
- Supplier:
- Abno
- Gene target:
- ERCC8 293T Cell Transient Overexpression Lysate(Denatured)
Related genes to: ERCC8 293T Cell Transient Overexpression Lysate(Denatured)
- Gene:
- ERCC8 NIH gene
- Name:
- ERCC excision repair 8, CSA ubiquitin ligase complex subunit
- Previous symbol:
- CKN1
- Synonyms:
- CSA
- Chromosome:
- 5q12.1
- Locus Type:
- gene with protein product
- Date approved:
- 1995-02-07
- Date modifiied:
- 2019-04-23
Related products to: ERCC8 293T Cell Transient Overexpression Lysate(Denatured)
Related articles to: ERCC8 293T Cell Transient Overexpression Lysate(Denatured)
- Cockayne Syndrome (CS) is an autosomal recessive, progressive developmental and neurodegenerative disease. Approximately 30% of cases are caused by mutations in the ERCC8/CSA gene. Patients with CS present with cutaneous photosensitivity, growth failure, shorter life span, and a progressive degeneration of the central nervous system. Loss-of-function mutations in CSA result in deficiencies in the transcription-coupled nucleotide excision repair (TC-NER). Currently, no therapies are available for these patients. Adeno-associated virus (AAV)-mediated gene therapy offers an opportunity to address this unmet need. We designed a new AAV vector encoding human CSA under a ubiquitous promoter. We tested the therapeutic efficacy of this AAV9-CSA vector by neonatal intracerebroventicular injection in the Csa-/-;Xpa-/- mouse model. Treatment with AAV9-CSA resulted in a significant increase in lifespan, and broad distribution of human CSA in the brain and heart, without evidence of vector-related toxicity. Despite clear therapeutic benefit, we also observed neuroradiological abnormalities, and neuropathologic alterations, including hypomyelination, astrocytosis, and microgliosis, as well as likely life-limiting transcriptomic alterations in liver at endpoint. Nonetheless, the success of these experiments paves the way for the first clinical translation of an AAV gene therapy for CS patients into humans. - Source: PubMed
Publication date: 2026/07/30
Batista Ana RitaScholand Aine CCallahan William SWatson McKenna KSion Cassandra MMola TylerO'Hara KennedyWentworth Simon ASena-Esteves William SKing Oliver DKing Robert MSena-Esteves Miguel - Cockayne syndrome (CS), primarily caused by autosomal recessive pathogenic variants in (CSB) or (CSA), is a transcription-coupled nucleotide excision repair disorder. CS frequently presents with features similar to primary mitochondrial disease (PMD), including leukodystrophy, lactic acidemia, and skeletal muscle mitochondrial DNA (mtDNA) depletion. How this mitochondrial phenotype arises at the cellular level, and whether it can be pharmacologically targeted, is not yet clear. - Source: PubMed
Publication date: 2026/05/26
Kose MelisMcCormick Elizabeth MKeith KelseyRemes CristinaHaroon SuraiyaNakamaru-Ogiso EikoFalk Marni J - Choosing an optimal combination of adeno-associated virus (AAV) capsid and promoter is key to achieving precise, efficient, and safe gene delivery. However, the limited packaging capacity of AAV can make incorporating large transgenes with strong promoters challenging. To address this, we screened several promoter designs derived from portions of the 5' untranslated regions (UTRs) of the human and DNA repair genes to generate a novel 126-base pair (bp) mini-promoter (CP040). We evaluated the expression capabilities of CP040 and its components and demonstrated that intravenous (i.v.) administration of AAVDJ vector harboring enhanced green fluorescent protein () driven by the CP040 promoter (AAVDJ-) in neonatal mice resulted in strong central nervous system (CNS) expression 6 weeks later. CP040 expression was compared with the chicken beta actin (CBA), human elongation factor 1 alpha (EF1α), and human synapsin 1 (hSYN) promoters following intracerebroventricular (ICV) and intrathecal (IT) AAVDJ administrations. The CP040 mini-promoter yielded comparable expression levels to CBA and hSYN promoters and higher levels than EF1α, with lower off-target expression in liver and kidneys. These initial characterizations support CP040 as a promising candidate to enhance AAV-mediated gene therapy targeting the CNS when cargo sequences cannot fit within AAV size constraints. - Source: PubMed
Publication date: 2026/01/29
Chauhan MonikaDaugherty Audrey LKhadir Fatemeh EllieDuzenli Ozgun FHoffman AlexandraWan OliviaTinklenberg Jennifer AKang Peter BAslanidi GeorgePacak Christina A - Cockayne syndrome is an ultra-rare (1:2.5 million) hereditary disease from the group of progeroid syndromes caused by pathogenic and probable-pathogenic variants in DNA repair genes (ERCC8, ERCC6, XPB (ERCC3), XPD (ERCC2) and XPG (ERCC5)) and characterized by abnormal photosensitivity, congenital cataract, microcephaly, sensorineural hearing loss, nervous system pathology and other multisystem changes. In this manuscript, for the first time in the Russian Federation, we present the results of a clinical and genetic study and follow-up of a Russian cohort of patients. - Source: PubMed
Publication date: 2026/03/07
Kungurtseva A LPopovich A VTikhonovich Yu VIvannikova T EKovalskaia V AVasiliev P AVitebskaya A V - /: Melanoma is the deadliest form of skin cancer. Resistance to alkylating agents such as Temozolomide (TMZ) and Dacarbazine (DTIC) limits their clinical benefit, as these drugs remain palliative options when immunotherapies and targeted treatments fail. CSA/ERCC8 is a key component of transcription-coupled nucleotide excision repair (TC-NER), a pathway responsible for removing UV-induced DNA lesions. In principle, loss of a DNA repair factor would be expected to increase carcinogenesis. However, although CSA loss-of-function causes Cockayne Syndrome (CS), affected patients do not exhibit increased skin cancer incidence, suggesting that CSA impairment promotes apoptosis rather than tumor development. This paradox raises the possibility that CSA inhibition may selectively target melanoma cell survival pathways. : The expression of CSA/ERCC8 was analyzed by qRT-PCR and Western blot. ERCC8 was silenced using antisense oligonucleotides. Cell viability, apoptosis, cell cycle progression, drug sensitivity, and DNA damage were assessed by functional assays, including IC50 determination and Bliss analysis for drug interactions. : We identified CSA/ERCC8 as a driver of melanoma chemoresistance. CSA was markedly overexpressed in primary and metastatic melanoma cells. ERCC8 silencing reduced proliferation, induced apoptosis, and significantly enhanced sensitivity to low doses of TMZ and DTIC while sparing normal cells. : CSA represents a promising therapeutic target to overcome chemoresistance in melanoma. Its inhibition enhances the efficacy and selectivity of alkylating agents, supporting its potential as a salvage strategy for refractory disease and warranting further preclinical and clinical investigation. - Source: PubMed
Publication date: 2026/02/17
Filippi SilviaValeri EmmaBartolocci ValeriaPaccosi ElenaGuzzon DilettaProietti-De-Santis Luca